Previous edition Contact

Werners Verbiest

Global Head, Janssen Diagnostics


11:30 - 12:45
From general to personalized

Track leader

Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.

In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.


Aiming High for Precision Medicine – A World Without Disease
Precision medicine’s greatest value may derive from shifting our unprecedented tools and technologies from the back end of diseases (treating diseases and their systems) to their front end: pre-disease interception and disease prevention.
Janssen Diagnostics’ vision of precision medicine goes beyond merely prescribing the right medicine to the right patient; it includes disease prevention, interception and cure. We envision a new era in healthcare, centered on precise medical interventions based on a person’s unique physiology and disease susceptibility, a future where disease interception and prevention is the norm. In order to achieve this, we need to tear down the barriers and silos between the players of healthcare industry and also embrace/integrate new players into the system and integrated solutions.

Kees Been
Lysosomal Therapeutics Inc.

Erik van de Berg

René Bernards
Qameleon Therapeutics & NKI

Annelien Bredenoord
UMC Utrecht

Carine van den Brink
AXON Lawyers

Danielle Curfs
Chemelot InSciTe
Jenny Dankelman
TU Delft
Diederik Dippel
Erasmus MC

Cornelia van Duijn
Erasmus MC

Lude Franke
Thibault Helleputte
Mark van Houdenhoven
St. Maartenskliniek
Henk Joos
Flanders Bio
Peter de Keizer
UMC Utrecht
Tim Knotnerus
AM-Pharma, PRIMER Professionals
Angus Livingstone
Oncode Institute
Travis McCready
Massachusetts Life Sciences Center

Mirjam Mol
Pivot Park

Barend Mons
Timothy Noël
Eindhoven University of Technology
Jacquelien Noordhoek
Dutch CF Foundation
Violet Petit-Steeghs
Athena Institute
Thomas Plochg

Gerard van Oortmerssen
Patientenplatform Sancomen

Anne Portwich
Elisabeth van Rossum
Erasmus MC
André van de Sande
Marlies Schijven
Hans Schikan
Topsector LSH
Hanneke Schuitemaker
Janssen Vaccines
Frits Schut
V.O. Patents & Trademarks
Marieke Schuurmans
UMC Utrecht
Jacob Seidell
Agaath Sluijter
Medical Delta
Thijs Spigt
Erasmus MC
Marianne van der Steen
Maastricht University
Maarten Steinbuch
Eindhoven University of Technology
Onno van de Stolpe
Werner Verbiest
Janssen Diagnostics
Martine de Vries

Edward van Wezel
BioGeneration Ventures

Jan van de Winkel

Loek Winter
DC Klinieken

Hanneke Heeres
Caroline Duterloo
Medical Delta
Paul Korte
Aart Jan van der Lelij
Erasmus MC
Werner Brouwer
Erasmus University
Arnout van Diermen
Novo Nordisk

Ton van der Steen
Erasmus MC & Medical Delta

Sven de Langen
Gemeente Rotterdam
Sponsors & Partners 2018
Main partner
Host sponsor
Host sponsor
Host sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Gold sponsor
Silver sponsor
Award sponsor
Award sponsor
© 2018 Innovation for Health